Protocol for: De Novo Nanobody Sequencing
Link to Full Protocol:
Abstract or Description:
Nanobodies are derived from a particular type of antibodies that exist in the blood of camelids (llama, alpaca, camel, dromedary, etc). In contrast to conventional antibodies that exist in all mammals (including human beings), the camelid “heavy-chain antibodies” (HCAbs) lack a light chain (the green domains in Fig.1). While conventional antibodies bind to antigen through the assembly of the variable domain of the heavy chain (VH) and that of the light chain (VL), the camelid HCAbs bind to antigen with a single domain called the VHH because of its size in the nm range, can be easily produced in bacteria or yeast in large quantities, is very stable and binds to the antigen with high affinities and specificities.
Nanobodies combine the advantages of conventional antibodies with important features of small molecule drugs. Like conventional antibodies, nanobodies show high target specificity, high affinity for their target and low inherent toxicity. However, like small molecule drugs they have the opportunity to inhibit enzymes and readily access receptor clefts, which is challenging with conventional antibodies.

Learn more about De Novo Nanobody Sequencing.
No Attachments
Posted By: candyswift on 10/9/2015 8:56:14 AM